ImmunoGen: Q2 FY 2016 Results (Immunogen) - Jan 30, 2016 - Anticipated initiation of enrollment in P2 trial in combination regimen for B-cell malignancies in H2 2016
Anticipated enrollment status • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Non-Hodgkin's Lymphoma • Oncology
|